Advancing peptides for the treatment of rare endocrine and metabolic disorders

We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.



Hypoparathyroidism is a rare endocrine disorder that is characterized by a deficiency in parathyroid hormone (PTH), resulting in dysregulation of calcium and phosphorus, two essential minerals in the body. Despite conventional treatments, patients frequently experience persistent life-altering symptoms and often develop secondary chronic conditions, such as kidney disease.

AZP-3601 is a parathyroid hormone (PTH) analog that targets a specific configuration of the PTH1 receptor to safely produce sustained levels of calcium in the blood and thereby control the symptoms of hypoparathyroidism. AZP-3601 has been designed to prevent chronic kidney disease by limiting the amount of calcium eliminated in the urine and to preserve bone integrity, an important benefit, since a large proportion of patients with hypoparathyroidism are middle-aged women often at an increased risk of developing osteoporosis.

We are preparing for the initiation of a Phase 1 program for AZP-3601 during the second half of 2020.

AZP-3601 (red) bound to the PTH1 receptor. Adapted from Zhao et al. Science 364:138, 2019. Image generated with the PyMOL Molecular Graphics System, Version 2.3.2 Schrödinger, LLC.


AZP-3404 is the first therapeutic peptide to leverage the biology of insulin-like growth factor binding protein 2 (IGFBP2) to stimulate multiple well-established pathways that restore the body’s regulation of fat and glucose metabolism.

At this time, we are generating additional data to prioritize potential target indications for AZP-3404. We are also conducting pre-investigational new drug activities in preparation for the initiation of a Phase 1 clinical trial in 2021.




Our global management team is composed of a highly dedicated group of senior executives with proven drug development expertise and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and metabolic disorders.

Thiery Abribat
Thierry Abribat, Ph.D.

Founder and Chief Executive Officer

Michael Culler
Michael Culler, Ph.D.

Chief Scientific Officer

Soraya Allas
Soraya Allas, M.D., PH.D.

VP, Clinical Development and Regulatory Affairs

Patrick Loustau
Patrick Loustau, M.S., M.A.

Chief Business Officer

Thomas Delale, Ph.D.
Thomas Delale, Ph.D.

VP, Portfolio Management

Delphine Martinez
Delphine Martinez, MBA

General Counsel

Pierre Legault

Chairman of the Board Directors, Amolyt Pharma

Felice Verduyn-van Weegen

Investment Manager at LSP

Naveed Siddiqi

Partner at Novo Ventures

Thierry Laugel

Managing Partner at Kurma Partners

Roy Amariglio

Principal at OrbiMed

Iyona Rajkomar

Partner at Pontifax

Thierry Abribat

CEO of Amolyt Pharma

Michael Culler

CSO of Amolyt Pharma

René Kuijten

Managing Partner at LSP

Meredith Fisher

Partner at Partners Healthcare Innovation Fund

OlivIer Martinez

Senior Investment Director at Bpifrance

Mounia Chaoui

Associate Director at Turenne Santé


Since its inception, Alizé Pharma 3, now Amolyt Pharma, has raised 3.3 M€ ($3.6 M) in seed funding, followed by a 67 M€ ($74 M) Series A financing from a strong international syndicate of investors.

Press Releases & Recent News

Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced the appointment of Pierre Legault, MBA, CPA as director and chairman of its board of directors…

Read More →

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and Metabolic Diseases

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic …

Read More →

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate Download a PDF copy …

Read More →

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.


15, chemin du Saquin
Espace Européen, Building G
69 130 Ecully

United States

Riverside Center
275 Grove Street, Suite 2-4035
Newton, MA, 02466

Scroll to Top